Author:
Chu Bin,Li Xiaoli,Fan Shiqiang,He Jinmei,Ge Xiaohong,Li Hui,Chen Changsheng,Wang Zhen,Wang Song,Li Boning
Abstract
Biodegradable materials are a next-generation invention for the treatment of congenital heart diseases. However, the corresponding technology used to develop ideal biomaterials still presents challenges. We previously reported the first biodegradable atrial septal defect (ASD) occluder made of poly-lactic acid (PLLA). Unfortunately, the PLLA occluder had a limited endothelialization effect. In this study, the surface of the occluder membrane was coated with sericin/CD34 antibodies to promote the growth of endothelial cells and the regeneration of defective tissue and enhance the repair of the atrial septal defect. The physicochemical properties of the coat on the surface of the fiber membrane were characterized. The sericin coat successfully covered the fiber surface of the membrane, and the thickness of the membrane increased with the sericin concentration. The swelling rate reached 230%. The microscopic observation of fluorescently labeled CD34 antibodies showed that the antibodies successfully attached to the fiber membrane; the fluorescence intensity of PLLA-SH5 was particularly high. The in vitro experiment showed that the PLLA-SH-CD34 fiber membrane was biocompatible and promoted the adhesion and proliferation of endothelial cells. According to our findings, the PLLA-SH-CD34 membrane provides a theoretical and technical basis for the research and development of novel biodegradable occluders.
Funder
Shenzhen Science and Technology Projects
Subject
Polymers and Plastics,General Chemistry
Reference32 articles.
1. The incidence of congenital heart disease;Hoffman;J. Am. Coll. Cardiol.,2002
2. Report from a visit to the cardiology centres in Kigali, Rwanda;Bialkowski;Adv. Interv. Cardiol./Postępy Kardiol. Interwencyjnej,2022
3. Percutaneous atrial septal occluder devices and cardiac erosion: A review of the literature;Crawford;Catheter. Cardiovasc. Interv.,2012
4. Biodegradable polymeric occluder for closure of atrial septal defect with interventional treatment of cardiovascular disease;Li;Biomaterials,2021
5. Cappellano, G., Comi, C., Chiocchetti, A., and Dianzani, U. (2019). Exploiting PLGA-based biocompatible nanoparticles for next-generation tolerogenic vaccines against autoimmune disease. Int. J. Mol. Sci., 20.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献